The life science group Sartorius and US-based startup TheWell Bioscience have agreed to partner on the further development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows. In addition to this, Sartorius will expand the portfolio of its lab division by distributing TheWell Bioscience's products and invest in a minority shareholding in the company.
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementationCustomers experience optimized facility equipment...
CAMBRIDGE, England--(BUSINESS WIRE)--Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins, is delighted to announce its collaboration with Sartorius, a global life science group, to supply growth factors and cytokines for stem cell and organoid research, as part of a comprehensive workflow solution.
MILFORD, Mass. and GOETTINGEN, Germany, June 5, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream biomanufacturing, expanding their joint agreement that began with upstream bioprocessing analytics. Software and hardware integrations between the Waters™ PATROL™ UltraPerformance Liquid Chromatography (UPLC™) Process
Sartorius and va-Q-tec announce a long-term partnership for the joint development of innovative transport systems for the biopharmaceutical industry
March 31 (Reuters) - Sartorius (SATG.DE) will acquire French lab technology company Polyplus for 2.4 billion euros ($2.62 billion) from private investors to strengthen its activities supplying cell and gene therapy companies.
Teknova and Sartorius BIA Separations Announce Collaboration to Address Critical Pain Point in Gene Therapy Process Development
GÖTTINGEN, Germany, Jan. 26, 2023 /PRNewswire/ -- Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability. Both divisions contributed to this development and, according to preliminary figures, recorded double-digit percentage growth in sales revenue and earnings year-over-year. For fiscal 2023, the company projects further growth and continued high profitability.
Sartorius has extended a strategic collaboration agreement with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. The companies will provide solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that aims to deliver industry-leading yield, purity, and potency. This collaboration will also focus on the development of comprehensive analytical techniques for the characterization of exosomes and the entire spectrum of extracellular vesicles (EVs) to establish quantitative strategies for quality control of exosome purification intermediates and final drug product.
Sartorius has appointed Maurice Phelan as President of Sartorius North America, succeeding Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, NY, currently employs more than 3,000 employees across 17 sites in the U.S. and Canada.